Information Provided By:
Fly News Breaks for April 22, 2016
SRPT
Apr 22, 2016 | 09:20 EDT
Needham analyst Chad Messer says he remains a buyer of Sarepta on yesterday's sell-off. The analyst continues to view accelerated approval for the company's eteplirsen as uncertain but possible. Messer reiterates a Buy rating and $53 price target on the shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT